Novo Nordisk A/S Revenue 2024

The Novo Nordisk A/S Revenue history

YEAR	REVENUE (undefined DKK)	GROSS MARGIN (%)
2029e	475.34	41,34
2028e	438.3	44,83
2027e	398.71	49,28
2026e	411.69	47,73
2025e	351.98	55,83
2024e	291.47	67,41
2023	232.26	84,60
2022	176.95	83,92
2021	140.8	83,20
2020	126.95	83,51
2019	122.02	83,97
2018	111.83	84,25
2017	111.7	84,21
2016	111.78	84,63
2015	107.93	85,00
2014	88.81	83,60
2013	83.57	83,08
2012	78.03	82,74
2011	66.35	81,03
2010	60.78	80,78
2009	51.08	79,56
2008	45.55	77,81
2007	41.83	76,59
2006	38.74	75,26
2005	33.76	72,82
2004	29.03	72,27

Novo Nordisk A/S Aktienanalyse

What does Novo Nordisk A/S do?

Novo Nordisk A/S is a Danish company specializing in the production of insulin and other diabetes medications. It was founded in 1923 and has its headquarters in Bagsværd, Denmark. Novo Nordisk is the world's largest manufacturer of insulin and one of the key players in the field of diabetes treatment. Novo Nordisk A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Novo Nordisk A/S's Sales Figures

The sales figures of Novo Nordisk A/S originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Novo Nordisk A/S’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Novo Nordisk A/S's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Novo Nordisk A/S’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Novo Nordisk A/S Stock

How much revenue did Novo Nordisk A/S generate this year?

Novo Nordisk A/S has achieved a revenue of 291.47 B DKK this year.

How much was the turnover of the company Novo Nordisk A/S compared to the previous year?

The revenue of Novo Nordisk A/S has increased by 25.49% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Novo Nordisk A/S?

The revenue of Novo Nordisk A/S is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Novo Nordisk A/S measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Novo Nordisk A/S so important for investors?

The revenue of Novo Nordisk A/S is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Novo Nordisk A/S pay?

Over the past 12 months, Novo Nordisk A/S paid a dividend of 14.15 DKK . This corresponds to a dividend yield of about 1.63 %. For the coming 12 months, Novo Nordisk A/S is expected to pay a dividend of 14.94 DKK.

What is the dividend yield of Novo Nordisk A/S?

The current dividend yield of Novo Nordisk A/S is 1.63 %.

When does Novo Nordisk A/S pay dividends?

Novo Nordisk A/S pays a quarterly dividend. This is distributed in the months of September, April, September, April.

How secure is the dividend of Novo Nordisk A/S?

Novo Nordisk A/S paid dividends every year for the past 26 years.

What is the dividend of Novo Nordisk A/S?

For the upcoming 12 months, dividends amounting to 14.94 DKK are expected. This corresponds to a dividend yield of 1.72 %.

In which sector is Novo Nordisk A/S located?

Novo Nordisk A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Novo Nordisk A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Novo Nordisk A/S from 3/26/2024 amounting to 6.4 DKK, you needed to have the stock in your portfolio before the ex-date on 3/22/2024.

When did Novo Nordisk A/S pay the last dividend?

The last dividend was paid out on 3/26/2024.

What was the dividend of Novo Nordisk A/S in the year 2023?

In the year 2023, Novo Nordisk A/S distributed 11.15 DKK as dividends.

In which currency does Novo Nordisk A/S pay out the dividend?

The dividends of Novo Nordisk A/S are distributed in DKK.